

Francine E Garrett-Bakelman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4679959/publications.pdf>

Version: 2024-02-01

42
papers

2,947
citations

471509

17
h-index

454955

30
g-index

43
all docs

43
docs citations

43
times ranked

5613
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13. <i>BioTechniques</i> , 2022, , .	1.8	0
2	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabb7695.	12.4	13
3	Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. <i>Blood Reviews</i> , 2022, 55, 100950.	5.7	9
4	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2688-2692.	7.2	7
5	Frequent somatic <i>TET2</i> mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. <i>Blood</i> , 2021, 138, 662-673.	1.4	30
6	An <i>Esrrb</i> and <i>Nanog</i> Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 630067.	3.7	8
7	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. <i>Nature Communications</i> , 2021, 12, 5406.	12.8	29
8	Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. <i>Cancer Discovery</i> , 2021, 11, 1542-1561.	9.4	133
9	Clonal Hematopoiesis Before, During, and After Human Spaceflight. <i>Cell Reports</i> , 2020, 33, 108458.	6.4	30
10	Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. <i>Cell Reports</i> , 2020, 33, 108448.	6.4	35
11	Multi-omic, Single-Cell, and Biochemical Profiles of Astronauts Guide Pharmacological Strategies for Returning to Gravity. <i>Cell Reports</i> , 2020, 33, 108429.	6.4	37
12	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. <i>IScience</i> , 2020, 23, 101844.	4.1	31
13	COCOA: coordinate covariation analysis of epigenetic heterogeneity. <i>Genome Biology</i> , 2020, 21, 240.	8.8	10
14	Temporal Telomere and DNA Damage Responses in the Space Radiation Environment. <i>Cell Reports</i> , 2020, 33, 108435.	6.4	40
15	Targeted detection and quantitation of histone modifications from 1,000 cells. <i>PLoS ONE</i> , 2020, 15, e0240829.	2.5	3
16	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
17	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
18	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0

#	ARTICLE	IF	CITATIONS
19	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
20	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
21	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
22	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
23	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
24	CD97 is a critical regulator of acute myeloid leukemia stem cell function. Journal of Experimental Medicine, 2019, 216, 2362-2377.	8.5	24
25	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer Discovery, 2019, 9, 872-889.	9.4	36
26	The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. Science, 2019, 364, .	12.6	576
27	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell, 2018, 33, 44-59.e8.	16.8	71
28	Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. Blood, 2017, 129, 1779-1790.	1.4	18
29	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i> - and <i>TET2</i> -Mutant Acute Myeloid Leukemia. Cancer Discovery, 2017, 7, 494-505.	9.4	94
30	Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discovery, 2017, 7, 868-883.	9.4	101
31	The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nature Medicine, 2017, 23, 1369-1376.	30.7	971
32	Mutant <i>IDH1</i> : a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics, 2016, 8, 945-957.	2.1	21
33	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	30.7	195
34	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 2016, 22, 792-799.	30.7	322
35	CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function. Blood, 2016, 128, 1077-1077.	1.4	3
36	Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution. Journal of Visualized Experiments, 2015, , e52246.	0.3	89

#	ARTICLE	IF	CITATIONS
37	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. Blood, 2015, 126, 306-306.	1.4	2
38	Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion. Blood, 2014, 124, 364-364.	1.4	0
39	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. Blood, 2014, 124, 69-69.	1.4	0
40	Differentiation therapy for IDH1/2 mutant malignancies. Cell Research, 2013, 23, 975-977.	12.0	8
41	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. Blood, 2013, 122, 3760-3760.	1.4	0
42	Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia. Blood, 2013, 122, 2499-2499.	1.4	1